These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 38814386)
21. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Campochiaro PA; Nguyen QD; Hafiz G; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane FE; Ophthalmology; 2013 Mar; 120(3):583-587. PubMed ID: 23218184 [TBL] [Abstract][Full Text] [Related]
22. Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre. Pockar S; Leal I; Chhabra R; Jones NP; Steeples LR Ocul Immunol Inflamm; 2023 Oct; 31(8):1572-1578. PubMed ID: 34124978 [TBL] [Abstract][Full Text] [Related]
24. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472 [TBL] [Abstract][Full Text] [Related]
25. Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment. Steeples LR; Pockar S; Jones NP; Leal I Clin Ophthalmol; 2021; 15():1433-1442. PubMed ID: 33854297 [TBL] [Abstract][Full Text] [Related]
26. Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN Carneiro A; Meireles A; Castro Sousa JP; Teixeira C Ther Adv Ophthalmol; 2020; 12():2515841420917768. PubMed ID: 32548568 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Currie CJ; Holden SE; Berni E; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143 [TBL] [Abstract][Full Text] [Related]
28. Scleral fixation of fluocinolone acetonide implant. Tabandeh H; Rezaei K Am J Ophthalmol Case Rep; 2020 Sep; 19():100775. PubMed ID: 32577584 [TBL] [Abstract][Full Text] [Related]
30. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation. Sadiq MA; Agarwal A; Soliman MK; Hanout M; Sarwar S; Do DV; Nguyen QD Expert Opin Drug Saf; 2015 Jul; 14(7):1147-56. PubMed ID: 25994877 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376 [TBL] [Abstract][Full Text] [Related]
32. Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits. Kane FE; Green KE J Ocul Pharmacol Ther; 2015 Feb; 31(1):11-6. PubMed ID: 25562126 [TBL] [Abstract][Full Text] [Related]
33. A New Approach for Diabetic Macular Edema Treatment: review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes. Estebainha R; Goldhardt R; Falcão M Curr Ophthalmol Rep; 2020 Mar; 8(1):1-10. PubMed ID: 32346496 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of 190 µg Fluocinolone Acetonide and 700 µg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis. Zarranz-Ventura J; Mali JO Clin Ophthalmol; 2020; 14():1697-1704. PubMed ID: 32606585 [TBL] [Abstract][Full Text] [Related]
35. Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review. Ribeiro F; Falcão MS J Ophthalmol; 2021; 2021():6678364. PubMed ID: 34055398 [TBL] [Abstract][Full Text] [Related]
36. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME). McCluskey JD; Kaufman PL; Wynne K; Lewis G Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396 [No Abstract] [Full Text] [Related]
37. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Holden SE; Currie CJ; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149 [TBL] [Abstract][Full Text] [Related]
38. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Chakravarthy U; Taylor SR; Koch FHJ; Castro de Sousa JP; Bailey C; Br J Ophthalmol; 2019 Aug; 103(8):1072-1077. PubMed ID: 30242062 [TBL] [Abstract][Full Text] [Related]
39. Alternative technique for the injection of fluocinolone acetonide (FAc) intravitreal implant (Iluvien Diago T; Fau SG; Roca JM Eur J Ophthalmol; 2023 May; 33(3):1501-1505. PubMed ID: 36632008 [TBL] [Abstract][Full Text] [Related]
40. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results. Jaffe GJ; Pavesio CE; Ophthalmology; 2020 Oct; 127(10):1395-1404. PubMed ID: 32624244 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]